News
Novo Nordisk, Maker of Obesity Drug Wegovy
Digest more
The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative ...
WEDNESDAY, Sept. 3, 2025 (HealthDay News) — The weight-loss drug Wegovy may lower the risk of heart attack, stroke or death ...
A class-action lawsuit accuses CVS Caremark of denying medically necessary treatments by stopping coverage of Zepbound, Eli ...
GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.
Novo Nordisk A/S (NYSE:NVO) on Sunday presented data from the STEER real-world study of evidence gathered from actual patient ...
A recent research from Novo Nordisk suggested that the weight-loss drug Wegovy may reduce the risk of cardiac arrest, death, ...
CVS Caremark is facing multiple federal lawsuits by patients challenging its decision to remove weight-loss drug Zepbound ...
Novo Nordisk’s popular weight loss drug, Wegovy, is the first and only GLP-1 medication approved to treat metabolic associated steatohepatitis, a serious condition marked by liver scarring. The FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback